




RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022



TwinLab Consolidated Holdings Inc. Rank 38 of 50



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022



TwinLab Consolidated Holdings Inc. Rank 38 of 50

The relative strengths and weaknesses of TwinLab Consolidated Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TwinLab Consolidated Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 141% points. The greatest weakness of TwinLab Consolidated Holdings Inc. is the variable Assets, reducing the Economic Capital Ratio by 194% points.

The company's Economic Capital Ratio, given in the ranking table, is -227%, being 1.8% points above the market average of -229%.

Input Variable	Value in 1000 USD
Assets Hidden Reserves	0
Assets, Current	17,371
Assets, Non-Current	6,781
General and Administrative Expense	68,663
Goodwill	576
Liabilities Hidden Reserves	0
Liabilities, Current	136,760
Liabilities, Non-Current	5,197
Other Assets	0
Other Compr. Net Income	0
Other Expenses	11,131
Other Liabilities	0
Other Net Income	-7,235
Property, Plant and Equipment, Net	140
Research and Development	0
Revenues	72,089

Output Variable	Value in 1000 USD
Liabilities	141,957
Assets	24,868
Expenses	79,794
Market Value Liabilities	141,957
Market Value Assets	24,868
Stockholders Equity	-117,089
Net Income	-14,940
Comprehensive Net Income	-14,940
Economic Capital Ratio	-227%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai